Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALLAS: Dronedarone in Permanent Atrial Fibrillation
NCT01151137Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Jul 2010
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 37
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Dronedarone with Placebo (2 arms). Primary endpoints: Composite of Stroke, Systemic Arterial Embolism, Myocardial Infarction, or Cardiovascular Death up to 1 year and Unplanned Cardiovascular Hospitalization or Death from Any Cause up to 1 year. Started Jul 2010; status: terminated.
02
Drugs
dronedarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01151137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01151137.